Boston Scientific gets European OK. Solasia to develop and market drug. Print E-mail
By Staff and Wire Reports   
Monday, 07 March 2011 19:31
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 07, 2011.

Boston Scientific Corp (NYSE:BSX) said it has received European regulatory approval for it's bare-metal stent technology called Omega, is designed to be easier to deliver and conform better to the artery, and remains on track to launch its Promus Element stent in the United States in mid-2012.  They also expects U.S. Food and Drug Administration approval in mid-2011 for its next-generation drug-eluting Taxus Element stent and in mid-2012 for its Promus Element stent. Taxus Element will be called Ion in the United States.  Promus Element will replace the Promus stent in Boston Scientific's product line that the company now co-markets with Abbott Laboratories (NYSE:ABT).

The original Promus is Abbott's popular Xience stent sold under the Promus name, with Abbott receiving about 40 percent of the profit.  Natick, Massachusetts-based Boston Scientific competes against Medtronic Inc (NYSE:MDT), Johnson & Johnson (NYSE:JNJ) and Abbott in the nearly $5 billion worldwide stent market.

Ziopharm, Solasia Pharma ink marketing deal for cancer drug - Solasia Pharma KK will develop and commercialize its experimental cancer drug darinaparsin in specific Asian and Pacific markets for milestone payments of up to $86 million as per Ziopharm Oncology Inc. (NASDAQ:ZIOP). Under the agreement, Solasia was given the exclusive license to develop and commercialize the injection and oral form of darinaparsin in Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, the Philippines and Thailand.

Along with an upfront payment of $5 million, Ziopharm will be entitled to receive up to $32.5 million in development based-milestone and up to $53.5 million in sales-based milestone payments.

Darinaparsinwas granted orphan drug status, on Jan. 20, 2011, by the U.S. Food and Drug Administration as a treatment for peripheral T-cell lymphoma (PTCL).

Also Monday:

Allied Healthcare International Inc. (NASDAQ: AHCI), a leading provider of flexible healthcare staffing services in the United Kingdom, announced today that its UK subsidiary, Allied Healthcare Group Limited, has acquired the homecare business of Health and Lifecare Options Limited (HALO).

Bionovo, Inc. (Nasdaq:BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that Dr. Isaac Cohen, O.M.D., Chairman and Chief Executive Officer, will be presenting at the Cowen and Company 31st Annual Healthcare Conference at 9:30 a.m. ET on Wednesday, March 9, 2011.

Boston Scientific Corporation (NYSE:BSX) today announced it has received CE Mark for its OMEGA(TM) Platinum Chromium Bare-Metal Coronary Stent System, the Company's third-generation coronary stenting technology.

Champions Biotechnology, Inc. (OTC: CSBR), today announced its operating results for its third fiscal quarter ended January 31, 2011.

Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced the publication of a research article titled "A Prospective Randomized Trial Using Blood Volume Analysis in Addition to Pulmonary Artery Catheter, Compared with Pulmonary Artery Catheter Alone, to Guide Shock Resuscitation in Critically Ill Surgical Patients" in the medical journal Shock (2011; 35(3):220-8).

Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will release financial results for the year ended December 31, 2010 on Thursday, March 10, 2011 before market open to be followed by a conference call at 11:00 a.m. Eastern Time.

Esterline Corporation (NYSE: ESL) (, a leading specialty manufacturer serving aerospace and defense markets, today announced that Mary L. Howell has been appointed to the company's board of directors.

Genesis Biopharma, Inc. (OTC Bulletin Board:GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named Marvin S. Hausman M.D. as Chief Science Officer.

Keryx Biopharmaceuticals (Nasdaq:KERX) today announced that the final dataset from the Phase 3 short-term clinical trial of Zerenex™ (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis has been selected for oral presentation at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings, to be held April 26-30, 2011 in Las Vegas, Nevada.

NeoStem, Inc. (NYSE Amex:NBS), an international biopharmaceutical company with operations in the U.S. and China, is pleased to announce that Jason Kolbert has joined the firm as Vice President of Strategic Business Development.

OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today that the Company's fourth quarter and full year 2010 financial results will be released on Thursday, March 10, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide a 2011 corporate outlook.

Boston Scientific Corporation (NYSE:BSX) today announced it has received CE Mark for its OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System, the Company's third-generation coronary stenting technology.

Southern Home Medical Equipment, Inc. (PINKSHEETS: SHOM), a Holding Company providing healthcare services, staffing and equipment to medical institutions, today announces a corporate overview for the shareholders and financial industry.

Stellar Pharmaceuticals Inc. ("Stellar" or "Company") (OTCQB:SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that, as of February 23, 2011, the Company's common shares ceased trading on the OCTBB and began trading on the OTCQB under the ticker symbol SLXCF.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus